"Is Immortality Within Reach?" Regenerative Bio Secures Tens of Millions in USD in Series Angel and Angel+ Funding

VCBeat learned at the earliest opportunity,Regenerative Bio, the world’s first anti-aging biotechnology R&D company driven by artificial intelligence and cloud-based supercomputing, announced the completion of its angel and angel+ funding rounds, totaling tens of millions of U.S. dollars.The angel round was led by IMO Ventures, with participation from K2VC (Xianfeng Changqing), Uphonest Capital, and Taihill Venture. The angel+ round was led by 5Y Capital, with participation from Yael Capital. Regenerative Bio will use the funds from this financing round to enhance its domestic laboratory facilities, optimize its AI screening platform, and promote its scientific anti-aging brand, LAIFE.

Regenerative Bio was founded in Boston, USA, incubated by the early-stage biotech fund Forcefield Venture. It returned to China and established its operations in 2021, dedicated to integrating AI-driven drug discovery technologies with biology to explore anti-aging ingredients, formulations, and therapies, addressing a series of age-related health issues and extending human healthspan.

On January 20, 2022, a major headline swept across multiple media outlets: a biotech startup named Altos Labs officially launched; meanwhile, the company announced that it had secured up to$3 billionWith its massive financing round, the world’s richest man and Amazon founder Jeff Bezos is a major shareholder. According to industry media STAT, this is the largest investment in the history of the biotechnology sector.

Altos Labs aims to discover cellular“Rejuvenation”The Mystery: Dedicated to researching cell reprogramming technologies to reshape cellular health, revitalize cells, and thereby achieve the effects of delaying aging and extending lifespan. To realize this ambitious goal, the company has recruitedFour Nobel Laureates and Top Scientists from Around the World in Related FieldsJoin together.

“Rejuvenation” and “anti-aging” have become buzzwords in recent years, with the rapid growth of related companies underscoring humanity’s timeless aspiration for eternal youth.

In the past, aging was largely viewed as an irresistible natural process. In recent years, however, we have increasingly classified aging within the spectrum of disease. Research indicates that the onset and progression of many diseases are closely linked to aging.“When people begin to recognize aging as a health issue, they will start attempting to study it using scientific methods.”Zhao Xuechen, Co-founder and CEO of the company, stated that this is the direct reason why many investors have begun to focus heavily on this sector. Additionally, the ravages of the pandemic have significantly stimulated the development of the entire biopharmaceutical industry. Industry tycoons such as Bill Gates and Jeff Bezos have substantially increased their investments in related fields, leading to a sharp rise in global capital’s attention to this sector.

“Go back five to ten years, and humanity’s understanding of the underlying mechanisms of aging was relatively vague. At that time, it would have been largely impractical for any company to enter this field, nor would investors have dared to assume the substantial risks required to support such ventures. But"As our understanding of the mechanisms of aging has deepened in recent years, more and more scientists have achieved breakthroughs in the field of anti-aging. The remaining question, therefore, is how to transform scientific challenges into engineering problems."

In its early development stage, Regenerative Bio focused on the research, development, and promotion of nutritional supplements with anti-aging effects. Its distinguishing feature lies inIntegrate AI-driven drug discovery technologies with biology to apply pharmaceutical logic to the nutritional supplement industry.

At first glance, this is truly surprising. Why have they chosen to take this approach? And how can the logic of AI-driven drug discovery be applied to the nutritional health and wellness industry?

“Globally, and particularly in China, the development of nutritional supplements is largely devoid of scientific research. Most companies simply encapsulate or tabletize raw ingredients with purported health benefits for consumer consumption,” Zhao Xuechen told VCBeat.Most nutritional supplements currently on the market lack rigorous scientific validation, and the absence of unified evaluation standards within the industry has led to a rather chaotic development of the domestic nutritional supplement market.—Related nutritional health products cannot guarantee the extent of their efficacy; they only ensure that they are non-toxic and harmless.

“We aim to transform the current state of this industry through fundamental scientific research at the foundational level, launching products that are safe, effective, and suitable for long-term use. Meanwhile, we believe this also represents the industry’s development trend. The new generation of consumers is beginning to possess their own discernment, and third-party agencies as well as certain independent media outlets in the market will conduct in-depth investigations into related products. Products relying solely on marketing will inevitably be eliminated.” Regenerative Bio seeks to cover the entire chain from foundational product development to scientific research, introducing pharmaceutical logic into the nutritional supplements industry and promoting the healthy development of the entire sector.

To continuously and efficiently identify ingredients and substance combinations with anti-aging efficacy, Regenerative Bio has established and will continue to optimize a pharmacological information database and knowledge graph encompassing known substances, including FDA-approved drugs, OTC monograph ingredients, dietary ingredients, and GRAS substances.

Based on this database and knowledge graph, Regenerative Bio has builtPASS, the world’s first AI-powered platform for screening anti-aging compounds, works in conjunction with high-content screening (HCS) experiments to comprehensively enhance the efficacy and stability of commercially viable anti-aging products in areas such as drug delivery, formulation, and ingredient ratios, thereby significantly improving R&D efficiency and reducing development costs.

Over the past year, the PASS platform has completed technical feasibility validation and achieved initial commercialization results.

In the B2B sector, Regenerative Bio empowers companies in the anti-aging industry chain—Cell Companion—through the PASS platform., the company has independently completed tens of millions of yuan in financing. Additionally, by providing technical output for this project, Regenerative Bio will generate annual revenue in the tens of millions. Furthermore, Regenerative Bio is currently in discussions with several other B2B companies regarding potential collaborations.

Although partnering with B-side companies can generate healthy cash flow, Regenerative Bio is not a company that focuses its business on the B-side.

Zhao Xuechen stated candidly that the team is more committed to building a brand that consumers follow and love, noting, “It is deeply fulfilling to serve as many people as possible with the best products and services.”

Therefore, in the consumer market, Regenerative Bio launched the "Scientific Anti-Aging" brand LAIFE,Meaning “LIFE with AI,” the brand is committed to its mission of “extending healthy, productive human lifespan” and guided by the philosophy of “Boundless Life,” to develop safe, effective, and sustainable next-generation anti-aging products.

LAIFE’s inaugural ANTI-AGING series is built around the NAD+ pathway. It deconstructs and redefines the mechanisms of action of the premier anti-aging compound Fisetin, Nicotinamide Riboside (NR), and β-Nicotinamide Mononucleotide (β-NMN). By integrating multi-source NAD+ precursors, regulating the NAD+/NADH ratio, facilitating metabolite excretion, and activating salvage pathways, the series establishes a comprehensive NAD+ endogenous cycle. Additionally, high-throughput screening has identified multiple synergistic agents with enhanced anti-inflammatory and antioxidant properties.It not only increased bioavailability by more than 180% but also addressed the issue of diminished efficacy associated with long-term use of related products. The product series achieved orders exceeding RMB 10 million in its first month on the market.

Furthermore, Regenerative Bio has begun preparations to address the diverse needs of individual consumers.“Oral Anti-Aging” New Nutrition Brand YOUNG&, focusing on the emerging female consumer demographic aged 25–35, to provide sustainable nutrition solutions for young consumers.

By applying pharmaceutical logic to the nutritional supplement industry, Regenerative Bio aims to infuse the sector with a foundation of scientific research and launch safer, more effective anti-aging health products. In the future, Regenerative Bio will commence the research and development of anti-aging therapeutics.

According to VCBeat, the core team members of Regenerative Bio graduated from world-renowned institutions such as Harvard University, the Massachusetts Institute of Technology (MIT), the University of California, Berkeley, and Imperial College London. Their professional backgrounds span across the biomedical, traditional fast-moving consumer goods (FMCG), internet, new consumption, and financial sectors, bringing extensive experience in both R&D and commercialization.

Zhao Xuechen, Co-Founder and CEOHolding a Master’s degree in Entrepreneurship from Babson College and a Bachelor’s degree in Management from the University of Nottingham Ningbo China, Zhao Xuechen was the youngest individual on the 2021 Forbes Under 30 list for Science & Healthcare. As a serial entrepreneur, she achieved a successful exit during her student years. Following this exit, Zhao served as Founding Partner at Taihill Venture, an early-stage deep tech fund based in Boston, where she was an early investor in companies such as Lightelligence, Kula Bio, and Manus Bio.

Dr. Feng, Co-Founder and CSO of the CompanyHe holds a postdoctoral fellowship in Chemistry and Chemical Biology from Harvard University, a Ph.D. in Synthetic Chemistry from the University of California, Berkeley, and a B.S. in Chemistry and Molecular Engineering from Peking University.

For CEO Zhao Xuechen, all his past experiences—whether working on the front lines of entrepreneurship, personally managing company operations, or navigating Boston’s venture capital community and building friendships with founders—have culminated in professional expertise and industry resources that now serve as strong support for his second entrepreneurial venture.

The co-founders share common values, possess complementary skills, and maintain mutual trust, which is one of the secrets behind Regenerative Bio’s rapid development. Additionally, the team’s extensive international background enables the company to integrate top-tier scientific resources from the United States with diverse commercial resources from China; the empowerment provided by these high-quality industrial resources constitutes another powerful engine accelerating the company’s growth.

This round of financing, backed by additional investments from multiple venture capital firms in China and the United States, signifies that Regenerative Bio’s international resources have reached a new level. We also express our hope that Regenerative Bio will bring more high-quality, safe, and effective anti-aging products to the market.

Liu Hai, Partner at IMO Ventures, stated, “There is no doubt that anti-aging research is a critical area with the greatest growth potential in the coming decades. In China, more than 75% of the population is in a state of sub-health, and these individuals are highly likely to experience a series of health issues as they age. By focusing on aging as its core research direction, Regenerative Bio can address these challenges innovatively through the discovery of novel substances, while also offering solutions via traditional supplements. This approach allows the company to serve the nutritional supplement market and resolve longstanding issues regarding the unknown safety profiles and difficult-to-verify efficacy of conventional products. We hope that Regenerative Bio will effectively integrate its outstanding R&D capabilities with market demand to become a world-leading developer of anti-aging products.”

Jing Xutian, Managing Director at Wuyuan Capital, stated, “Aging has gradually emerged as a hot research area in recent years, harboring significant development opportunities amidst uncertainty. According to the research objectives outlined by the NIH (National Institute on Aging), it is particularly crucial to understand the underlying mechanisms of aging and their associations with related diseases. Regenerative Bio’s approach of constructing a pharmacological information knowledge graph and leveraging artificial intelligence tools for exploratory research offers an efficient solution. Furthermore, introducing new methodologies from drug discovery and AI into the nutritional supplement industry can greatly accelerate the R&D and innovation of high-value new products, thereby driving the growth of China’s nutritional health market. We hope this young entrepreneurial team will achieve outstanding results in the emerging field of aging.”

Guo Wei, Founding Partner of Uphonest Capital, stated, “Aging is an enduring theme in human development. With recent advances in biotechnology, interest in the longevity sector has surged in Silicon Valley. Whether it is Altos Labs, which attracted $3 billion in investment heavily backed by Amazon founder Jeff Bezos, or Apollo’s raising of a $180 million fund to position itself in the longevity space, these developments all indicate that anti-aging technologies hold significant promise for the future. As the first company to explore anti-aging approaches through an artificial intelligence-driven framework, Regenerative Bio is well-positioned to leverage its advantages in efficiency and cost-effectiveness to identify effective anti-aging solutions ahead of others. We believe that Regenerative Bio has the potential to become a China-born anti-aging R&D company with global impact.”

Yang Runxin, Vice President of Xianfeng Changqing, stated, “Applying AI-driven drug discovery technologies to the development of anti-aging products is a bold and highly innovative approach. Regenerative Bio’s founding team, with its interdisciplinary expertise spanning both science and business, is well-positioned to address new challenges through novel methods. Xianfeng remains optimistic about the consumer healthcare sector and hopes that Regenerative Bio will leverage its strengths to build a tech-enabled anti-aging brand that is both impactful and human-centric.”